Works matching AU Yoon, Sung-Soo

Results: 190
    1
    2
    3

    Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study.

    Published in:
    International Journal of Cancer, 2025, v. 157, n. 3, p. 526, doi. 10.1002/ijc.35411
    By:
    • Yoon, Seug Yun;
    • Yoon, Sung‐Soo;
    • Yang, Deok‐Hwan;
    • Lee, Gyeong‐Won;
    • Sohn, Sang Kyun;
    • Shin, Ho‐Jin;
    • Bae, Sung Hwa;
    • Choi, Chul Won;
    • Choi, Eun‐Ji;
    • Cheong, June‐Won;
    • Bang, Soo‐Mee;
    • Park, Joon Seong;
    • Oh, Suk Joong;
    • Park, Yong;
    • Park, Young Hoon;
    • Lee, Sung‐Eun
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17

    Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.

    Published in:
    Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-95287-x
    By:
    • Mizuno, Shinichi;
    • Yamaguchi, Rui;
    • Hasegawa, Takanori;
    • Hayashi, Shuto;
    • Fujita, Masashi;
    • Zhang, Fan;
    • Koh, Youngil;
    • Lee, Su-Yeon;
    • Yoon, Sung-Soo;
    • Shimizu, Eigo;
    • Komura, Mitsuhiro;
    • Fujimoto, Akihiro;
    • Nagai, Momoko;
    • Kato, Mamoru;
    • Liang, Han;
    • Miyano, Satoru;
    • Zhang, Zemin;
    • Nakagawa, Hidewaki;
    • Imoto, Seiya
    Publication type:
    Article
    18
    19
    20
    21
    22

    Comprehensive clinico‐genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm.

    Published in:
    British Journal of Haematology, 2025, v. 206, n. 4, p. 1228, doi. 10.1111/bjh.20022
    By:
    • Lee, Ji Hyun;
    • Oh, Sung‐Yong;
    • Lee, Taek Gyu;
    • Lee, Seung‐Tae;
    • Kim, Namhee;
    • Pak, Min Gyoung;
    • Yoon, Sung‐Soo;
    • Koh, Youngil;
    • Byun, Ja Min;
    • Yoon, Dok Hyun;
    • Jo, Jae‐Cheol;
    • Yang, Deok‐Hwan;
    • Ahn, Seo‐Yeon;
    • Eom, Hyeon Seok;
    • Lee, Hyewon;
    • Lee, Ji Yun;
    • Won, Jong Ho;
    • Yhim, Ho‐Young;
    • Lee, Ho Sup;
    • Kim, Won Seog
    Publication type:
    Article
    23
    24
    25
    26
    27

    Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.

    Published in:
    British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
    By:
    • Plesner, Torben;
    • Dimopoulos, Meletios A.;
    • Oriol, Albert;
    • San‐Miguel, Jesus;
    • Bahlis, Nizar J.;
    • Rabin, Neil;
    • Suzuki, Kenshi;
    • Yoon, Sung‐Soo;
    • Ben‐Yehuda, Dina;
    • Cook, Gordon;
    • Goldschmidt, Hartmut;
    • Grosicki, Sebastian;
    • Qin, Xiang;
    • Fastenau, John;
    • Garvin, Wendy;
    • Carson, Robin;
    • Renaud, Thomas;
    • Gries, Katharine S.
    Publication type:
    Article
    28
    29
    30
    31
    32

    Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).

    Published in:
    Annals of Hematology, 2023, v. 102, n. 8, p. 2233, doi. 10.1007/s00277-023-05308-0
    By:
    • Kim, Mihee;
    • Lee, Je-Jung;
    • Min, Chang-Ki;
    • Lee, Ji Yun;
    • Jo, Jae-Cheol;
    • Yoon, Sung-Soo;
    • Lim, Sung-Nam;
    • Do, Young Rok;
    • Kim, Kihyun;
    • Lee, Jae Hoon;
    • Yoo, Kwai Han;
    • Bae, Sung Hwa;
    • Yi, Jun Ho;
    • Jung, Jongheon;
    • Eom, Hyeon-Seok;
    • Jung, Sung-Hoon
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.

    Published in:
    EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
    By:
    • Richardson, Paul G.;
    • Facon, Thierry;
    • Venner, Christopher P.;
    • Bahlis, Nizar J.;
    • Offner, Fritz;
    • White, Darrell;
    • Karlin, Lionel;
    • Benboubker, Lotfi;
    • Voog, Eric;
    • Yoon, Sung‐Soo;
    • Suzuki, Kenshi;
    • Shibayama, Hirohiko;
    • Zhang, Xiaoquan;
    • Villarreal, Miguel;
    • Twumasi‐Ankrah, Philip;
    • Labotka, Richard;
    • Rifkin, Robert M.;
    • Lonial, Sagar;
    • Kumar, Shaji K.;
    • Rajkumar, S. Vincent
    Publication type:
    Article
    40
    41
    42
    43

    Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. 785, doi. 10.1016/j.clml.2021.06.005
    By:
    • Mateos, Maria-Victoria;
    • Dimopoulos, Meletios A.;
    • Cavo, Michele;
    • Suzuki, Kenshi;
    • Knop, Stefan;
    • Doyen, Chantal;
    • Lucio, Paulo;
    • Nagy, Zsolt;
    • Pour, Ludek;
    • Grosicki, Sebastian;
    • Crepaldi, Andre;
    • Liberati, Anna Marina;
    • Campbell, Philip;
    • Yoon, Sung-Soo;
    • Iosava, Genadi;
    • Fujisaki, Tomoaki;
    • Garg, Mamta;
    • Iida, Shinsuke;
    • Bladé, Joan;
    • Ukropec, Jon
    Publication type:
    Article
    44

    Poster: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01540-8
    By:
    • Assouline, Sarit;
    • Kim, Won Seog;
    • Sehn, Laurie H.;
    • Schuster, Stephen J.;
    • Cheah, Chan Yoon;
    • Nastoupil, Loretta J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Matasar, Matthew J.;
    • Diefenbach, Catherine;
    • Gregory, Gareth P.;
    • Bartlett, Nancy L.;
    • Wei, Michael C.;
    • Doral, Michelle Y.;
    • Yin, Shen;
    • Negricea, Raluca;
    • Li, Chi-Chung;
    • Penuel, Elicia;
    • Huang, Huang;
    • Budde, L. Elizabeth
    Publication type:
    Article
    45
    46

    A Prospective, Multicenter Phase II Study of Consolidation with Cyclophosphamide, Bortezomib and Dexamethasone (CVD) in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation; The KMM130 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e291, doi. 10.1016/j.clml.2019.09.478
    By:
    • Eom, Hyeon-Seok;
    • Jung, Jongheon;
    • Kim, Kihyun;
    • Min, Chang Ki;
    • Lee, Je-Jung;
    • Yoon, Sung-Soo;
    • Lee, Jae Hoon;
    • Kim, Jin Seok;
    • Shin, Ho-Jin;
    • Bang, Soo-Mee;
    • Sohn, Sang Kyun;
    • Suh, Cheolwon
    Publication type:
    Article
    47
    48
    49

    Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S247, doi. 10.1016/j.clml.2019.07.151
    By:
    • Bartlett, Nancy L.;
    • Sehn, Laurie H.;
    • Assouline, Sarit;
    • Bosch, Francesc;
    • Diefenbach, Catherine M.;
    • Flinn, Ian;
    • Hong, Jung Yong;
    • Kim, Wonseog S.;
    • Matasar, Matthew;
    • Nastoupil, Loretta;
    • Schuster, Stephen J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Bender, Brendan;
    • Chu, Wayne;
    • Hernandez, Genevive;
    • Kwan, Antonia;
    • McCall, Bruce;
    • Sison, Iris;
    • Wang, Cunlin
    Publication type:
    Article
    50